Drugs / ieramilimab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03742349 | Jan 2019 → Feb 2023 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02460224 | Jun 2015 → Dec 2020 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03484923 | Sep 2018 → Dec 2022 | melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03499899 | Jul 2018 → Feb 2020 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03365791 | Jan 2018 → Feb 2019 | diffuse large B-cell lymphoma, esophageal adenocarcinoma, gastric adenocarcinoma, ovarian adenocarcinoma +3 | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ieramilimab | “Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” PMID 35217575 ↗ Feb 2022 |
| Known as | Humanised imp-701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298009 ↗ |
| Known as | LAG525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03742349 ↗ |
| Known as | NVP-LAG525 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298009 ↗ |
| Action | Inhibit | “LAG-3 inhibitor ieramilimab (LAG525)” PMID 35217575 ↗ Feb 2022 |
| Modality | Monoclonal antibody | “humanized anti-LAG-3 IgG4 antibody” NCT03365791 ↗ |
| Route | Intravenous | “LAG525 was administered via intravenous (i.v.) infusion” NCT02460224 ↗ |
| Target | LAG3 | “tumor target (LAG-3) suppression with 600 mg ieramilimab Q4W was predicted to be similar to the Q4W, RP2D schedule.” PMID 35217575 ↗ Feb 2022 |